Which class of drugs does ensifentrine-Ohtuvayre belong to and its position and role in treatment?

Ensifentrine (Ensifentrine), trade name: Ohtuvayre, is a new inhaled drug specially used for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). It provides dual effects of improving airway patency and reducing inflammation through a unique dual phosphodiesterase inhibition mechanism.

Ohtuvayre Belongs to the category of "miscellaneous respiratory drugs" (Miscellaneous respiratory agents) category, specifically the first approved inhaled dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitors. This mechanism makes it uniquely positioned in the treatment of COPD .

In clinical studies, Ohtuvayre showed significant efficacy:

1.Improve lung function and reduce symptoms such as wheezing, coughing, chest tightness and shortness of breath;

2.Reduce the frequency of acute exacerbations and reduce hospitalization rates;

3.Compared with traditional inhaled corticosteroids and bronchodilators, it has fewer side effects, especially in elderly patients.

However, Ohtuvayre also has some limitations:

1.Need to use a nebulizer for inhalation, which is inconvenient to use;

2.The higher price may affect the patient’s financial burden;

3. It has not been approved in all countries and regions, limiting its global accessibility.

In short, Ohtuvayre , as a new COPD maintenance treatment drug, has shown good efficacy in improving symptoms and reducing acute exacerbations with its unique dual phosphodiesterase inhibition mechanism. However, limitations of its use and cost issues still need to be considered in clinical practice.

References:https://www.drugs.com/